blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3003489

EP3003489 - CYTOTOXIC AGENTS FOR THE TREATMENT OF CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  24.06.2022
Database last updated on 15.11.2024
FormerThe patent has been granted
Status updated on  16.07.2021
FormerGrant of patent is intended
Status updated on  23.04.2021
FormerExamination is in progress
Status updated on  30.03.2021
FormerGrant of patent is intended
Status updated on  22.12.2020
FormerExamination is in progress
Status updated on  22.11.2019
FormerRequest for examination was made
Status updated on  12.09.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024  [2024/41]
Applicant(s)For all designated states
CytRx Corporation
11726 San Vicente Blvd.
Los Angeles, CA 90049 / US
[2016/15]
Inventor(s)01 / LEVITT, Daniel
50 Parker Avenue
San Francisco, CA 94118 / US
 [2016/15]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2016/15]
Application number, filing date14807006.304.06.2014
[2016/15]
WO2014US40872
Priority number, dateUS201361831219P05.06.2013         Original published format: US 201361831219 P
[2016/15]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014197569
Date:11.12.2014
Language:EN
[2014/50]
Type: A1 Application with search report 
No.:EP3003489
Date:13.04.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 11.12.2014 takes the place of the publication of the European patent application.
[2016/15]
Type: B1 Patent specification 
No.:EP3003489
Date:18.08.2021
Language:EN
[2021/33]
Search report(s)International search report - published on:US11.12.2014
(Supplementary) European search report - dispatched on:EP11.01.2017
ClassificationIPC:A61P35/00, A61K45/06, A61K47/54
[2020/46]
CPC:
A61K31/704 (EP,KR,US); A61K45/06 (EP,KR,US); A61K47/545 (EP,KR,US);
A61K47/6809 (KR); A61P25/00 (EP,US); A61P35/00 (EP,US);
A61P35/02 (EP,US); A61P35/04 (EP,KR,US); C07H15/26 (EP,US) (-)
Former IPC [2017/06]A61P35/00, A61K45/06
Former IPC [2016/15]A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/15]
Extension statesBA05.01.2016
ME05.01.2016
TitleGerman:ZYTOTOXISCHE MITTEL ZUR BEHANDLUNG VON KREBS[2016/15]
English:CYTOTOXIC AGENTS FOR THE TREATMENT OF CANCER[2016/15]
French:AGENTS CYTOTOXIQUES DESTINÉS AU TRAITEMENT DU CANCER[2016/15]
Entry into regional phase05.01.2016National basic fee paid 
05.01.2016Search fee paid 
05.01.2016Designation fee(s) paid 
05.01.2016Examination fee paid 
Examination procedure05.01.2016Examination requested  [2016/15]
13.09.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
09.11.2017Amendment by applicant (claims and/or description)
29.11.2019Despatch of a communication from the examining division (Time limit: M04)
07.04.2020Reply to a communication from the examining division
24.04.2020Despatch of a communication from the examining division (Time limit: M04)
01.07.2020Reply to a communication from the examining division
23.12.2020Communication of intention to grant the patent
29.03.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
29.03.2021Fee for grant paid
29.03.2021Fee for publishing/printing paid
03.05.2021Communication of intention to grant the patent
08.07.2021Receipt of the translation of the claim(s)
Opposition(s)19.05.2022No opposition filed within time limit [2022/30]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
09.11.2017Request for further processing filed
09.11.2017Full payment received (date of receipt of payment)
Request granted
23.11.2017Decision despatched
The application is deemed to be withdrawn due to failure to indicate the wish to proceed further with the application
09.11.2017Request for further processing filed
09.11.2017Full payment received (date of receipt of payment)
Request granted
23.11.2017Decision despatched
Fees paidRenewal fee
27.06.2016Renewal fee patent year 03
13.11.2017Renewal fee patent year 04
12.06.2018Renewal fee patent year 05
13.06.2019Renewal fee patent year 06
15.06.2020Renewal fee patent year 07
14.06.2021Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
30.06.201704   M06   Fee paid on   13.11.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.06.2014
AL18.08.2021
AT18.08.2021
CY18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
MT18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
TR18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
[2024/41]
Former [2024/29]HU04.06.2014
AL18.08.2021
AT18.08.2021
CY18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
TR18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2024/22]HU04.06.2014
AL18.08.2021
AT18.08.2021
CY18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
MK18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2024/20]HU04.06.2014
AL18.08.2021
AT18.08.2021
CY18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2024/18]HU04.06.2014
AL18.08.2021
AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2023/08]AL18.08.2021
AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
MC18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/36]AL18.08.2021
AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
IT18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SI18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/29]AL18.08.2021
AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/26]AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SK18.08.2021
SM18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/24]AT18.08.2021
CZ18.08.2021
DK18.08.2021
EE18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RO18.08.2021
RS18.08.2021
SE18.08.2021
SK18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/21]AT18.08.2021
DK18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RS18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/16]AT18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
NL18.08.2021
PL18.08.2021
RS18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/10]AT18.08.2021
ES18.08.2021
FI18.08.2021
HR18.08.2021
LT18.08.2021
LV18.08.2021
PL18.08.2021
RS18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
GR19.11.2021
IS18.12.2021
PT20.12.2021
Former [2022/09]AT18.08.2021
ES18.08.2021
FI18.08.2021
LT18.08.2021
RS18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
PT20.12.2021
Former [2022/08]AT18.08.2021
ES18.08.2021
FI18.08.2021
LT18.08.2021
SE18.08.2021
BG18.11.2021
NO18.11.2021
Former [2022/07]AT18.08.2021
LT18.08.2021
NO18.11.2021
Documents cited:Search[I]WO2011131314  (KTB TUMORFORSCHUNGS GMBH [DE], et al) [I] 13,14,16,18,19* page 16, line 16; example 1 *;
 [X]  - GABATHULER ET AL, "Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier", THERAPEUTIC DELIVERY, FUTURE SCIENCE LTD, GB, (20101001), vol. 1, no. 4, doi:10.4155/TDE.10.35, ISSN 2041-5990, pages 571 - 586, XP008177007 [X] 1-3 * page 579 *

DOI:   http://dx.doi.org/10.4155/tde.10.35
 [XI]  - Christophe Rousselle ET AL, "New Advances in the Transport of Doxorubicin through the Blood-Brain Barrier by a Peptide Vector-Mediated Strategy", Molecular Pharmacology, UNITED STATES, (20000401), page 679, URL: http://molpharm.aspetjournals.org/content/57/4/679.full-text.pdf, XP055327527 [X] 1-10 * the whole document * [I] 1-10
 [X]  - NATALE R B ET AL, "Pharmacokinetic study of aldoxorubicin in solid tumor patients", 49TH ANNU MEET AM SOC CLIN ONCOL (A,, (20130101), XP009192754 [X] 1-12,15-17 * the whole document *
 [X]  - Anonymous, "NCT01706835 on 2012_11_05: ClinicalTrials.gov Archive", (20121105), URL: https://clinicaltrials.gov/archive/NCT01706835/2012_11_05, (20161208), XP055327492 [X] 1-12,15 * the whole document *
International search[Y]US2012135914  (DEMEULE MICHEL [CA], et al) [Y] 1-7, 17, 18 * entire document *;
 [A]US2012195832  (KRATZ FELIX [DE]) [A] 1-7, 17-25, 35-43, 53-61, 71, 72* entire document *;
 [XY]US2013040905  (KRATZ FELIX [DE]) [X] 19-25, 35-43, 53-61, 71, 72 * entire document * [Y] 1-7, 17, 18
ExaminationWO2014093815
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.